Psoriasis Climate Heats Up: Biosimilar Tsunami

Drs Steve Feldman and Andrew Blauvelt have a fascinating chat about contrasts and similarities between biologics and biosimilars, covering pharmacoeconomic and legal differences between the US and Europe.

Relevant disclosures can be found with the episode show notes on Medscape (https://www.medscape.com/ca8/p04/podcast-psoriasis-s2-ep5-2026a10005mx). The topics and discussions are planned, produced, and reviewed independently of advertisers. This podcast is intended only for US healthcare professionals.

Resources

Biosimilar Drugs for Psoriasis: Principles, Present, and Near Future https://pubmed.ncbi.nlm.nih.gov/29549597/

International Psoriasis Council https://psoriasiscouncil.org/

Biosimilars for Psoriasis: Clinical Studies to Determine Similarity https://pubmed.ncbi.nlm.nih.gov/27639072/

Safety, Efficacy and Drug Survival of Biologics and Biosimilars for Moderate-to-severe Plaque Psoriasis https://pubmed.ncbi.nlm.nih.gov/29094341/

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.